People Smell Great! Human Sniffers Sensitive as Dogs’ – Live Science

As you read this, take a whiff. What smells do you detect? How do these smells affect how you feel?

It's rare that people consciously take in the smells around them, but a new review argues that the human sense of smell is more powerful than it's usually given credit for, and that it plays a bigger role in human health and behavior than many medical experts realize.

"The fact is the sense of smell is just as good in humans as in other mammals, like rodents and dogs,"John McGann, a neuroscientist at Rutgers University-New Brunswick in New Jersey and the author of the new review, said in a statement.

People often think of dogs and rats as the superior sniffers in the animal kingdom, but humans also have an extremely keen sense of smell, McGann argued in the review, which was published today (May 11) in the journal Science. In fact, humans can discriminate among 1 trillion different odors, McGann wrote, far more than a commonly cited claim that people can detect only about 10,000 different smells. [10 Things That Make Humans Special]

By overlooking humans' keen smelling abilities, medicine may be missing a key component of human health, McGann said. Smell influences human behavior, from stirring up memories to attracting sexual partners to influencing mood to shaping taste, he said. It's no coincidence that the French word for smell, "sentir," also means to feel; emotion and smell are often intricately linked.

When considering the senses, there's a reason smell is often shunted to third place behind sight and hearing, McGann wrote.

It started in the 19th century, when Paul Broca, a French brain surgeon and anthropologist, observed that humans have proportionately smaller olfactory, or smell-related, organs compared with other animals, according to the review. Broca also noted that people don't exhibit odor-driven behavior to the same degree that other mammals do.

This led Broca to hypothesize in his 1879 writings that smell had taken a backseat role to the other senses in humans in exchange for free will. Years later, Sigmund Freud piggybacked on the idea that human smell is inferior to other senses, suggesting that the sense of smell could not dominate a rational person, according to the review.

McGann called these conclusions a "gross oversimplification," but they were then further supported by later research. For example, studies from the 20th century found that rats and mice have genes for about 1,000 different kinds of receptors that are activated by odors, compared with about 400 such receptors in humans.

It's true that humans have relatively smaller olfactory organs and fewer odor-detecting genes compared with other animals. However, the power of the human brain more than makes up for this.

"The truth is that 400 different receptors still offer a tremendous range. There are very few odors that humans can't smell despite having practically fewer receptors than rats, mice and dogs," McGann told Live Science. Part of the reason humans can detect so many odors is thanks to their "much more complicated and powerful brain that's interpreting that information."

When a person smells something, odor molecules bind to receptors in the nose. These receptors send information about the molecules to the human olfactory bulb in the brain, which then sends signals to other areas of the brain to help identify scents. [Tip of the Tongue: The 7 (Other) Flavors Humans May Taste]

This is different from the way smell works in dogs, McGann said. Dogs have a "pump" in their noses that's designed to take in chemicals in liquid form (say, on the side of a fire hydrant) for identification, he said. Because the smelling mechanisms are so different, it's hard to compare humans to dogs, McGann said.

Many studies have linked the humans sense of smell to certain medical conditions.

Dr. Dolores Malaspina, a psychiatrist at New York University Langone Medical Center, agreed that smell can play an important role in medicine. Malaspina was not involved in the new review.

Malaspina has long used smell to help diagnose certain diseases, and her research has connected the human sense of smell with both schizophrenia and depression.

"Smell among schizophrenia patients is often either distorted or decreased," she told Live Science.

Malaspina has also shown that a loss of smell can lead to depression. This may be linked to how odors trigger the growth of neurons, she said. [10 Things You Didn't Know About the Brain]

"There's evidence that these stimulations of the brain by odors may drive the making of new brain cells," she said.

Loss of smell has been linked to other health problems as well. A 2016 study showed that a loss of the ability to detect scents was associated with early signs of Alzheimer's disease. And sobering research from 2014found that a loss of smell may predict death within five years.

As people age, many gradually lose their sense of smell. Research has shown that 75 percent of people lose at least part of their sense of smell by age 80.

It's all the more reason, McGann said, to appreciate the power of human smell and its role in human health.

"When you lose your sense of smell, it's actually a big deal. It influences your ability to take pleasure in food and daily life," McGann said. "There's a significant impact of losing your sense of smell that's not yet fully understood."

Originally published on Live Science.

Continue reading here:
People Smell Great! Human Sniffers Sensitive as Dogs' - Live Science

Genetics – Official Site

The Genetics Society of America (GSA), founded in 1931, is the professional membership organization for scientific researchers and educators in the field of genetics. Our members work to advance knowledge in the basic mechanisms of inheritance, from the molecular to the population level.

Online ISSN: 1943-2631

Read the original:
Genetics - Official Site

Disentangling chloroplast genetics: Scientists isolate a critical gene … – Phys.Org

May 11, 2017 Japanese scientist have isolated and characterized a protein in chloroplasts that is essential for proper nucleoid segregation. Credit: Kyoto University

Proper DNA inheritance is essential for healthy cell growth and division. The same goes for the genetic material found in chloroplasts: the energy centers of all plant cells.

Chloroplast genomeslikely vestiges of ancestral bacteriaare organized into DNA-protein complexes called nucleoids. While significant work has been done to understand the dynamics of DNA in the nuclei of plant cells, little is known about the dynamics of chloroplast nucleoids.

Now Yusuke Kobayashi and Yoshiki Nishimura of Kyoto University, Osami Misumi of Yamaguchi University, and other collaborators have isolated and characterized a protein in chloroplasts that is essential for proper nucleoid segregation. Their findings were published recently in the journal Science.

"To understand the dynamics of chloroplast nucleoids, we focused on their behavior during chloroplast division in the green alga Chlamydomonas reinhardtii," explains Nishimura.

"We screened about 6,000 specimens with random mutations in their DNA and then isolated the ones with defective nucleoid segregation."

One of these mutants was found to have a defect in a gene the team calls moc1, for "Monokaryotic Chloroplast 1". The chloroplasts in this mutant possessed only a single nucleoid, and showed unequal segregation during chloroplast division. A homologous moc1 gene was then found in a land plant commonly used for research, Arabidopsis thaliana. When mutated, the researchers discovered that these organisms exhibit growth defects and abnormal nucleoid segregation.

After extensive analysis of this new gene, the team discovered that moc1 functions as a chloroplast-specific 'Holliday junction resolvase', which Nishimura continues, "is very important in untangling a DNA structure called Holliday junctions. These genes have never been found in chloroplasts, until now."

Continuing with their study, the researchers successfully visualized the activity of moc1 on Holliday junctions through the use of high-speed atomic force microscopy and DNA origami technology. They observed moc1 binding to the core of Holliday junctions and cutting them symmetrically.

The team's discovery improves understanding of the highly complex structures maintaining chloroplast DNA, whose proper functioning is essential for good cell health.

Explore further: A mutation giving leaves with white spots has been identified

More information: "Holliday junction resolvases mediate chloroplast nucleoid segregation" Science (2017). science.sciencemag.org/cgi/doi/10.1126/science.aan0038

Journal reference: Science

Provided by: Kyoto University

Garden and potted plants with white spots on their leaves are so popular that they are specially selected for this feature. An international research team has now identified a new mutation in the plant Lotus japonicus which ...

Researchers of Kumamoto University in Japan have succeeded in the world's first visualization of a peptidoglycan 'wall' present in the chloroplasts of bryophytes (moss plants). Until now, chloroplasts of green plants were ...

Researchers at Ruhr-Universitt Bochum have analysed how green algae manufacture complex components of a hydrogen-producing enzyme. The enzyme, known as the hydrogenase, may be relevant for the biotechnological production ...

Researchers at Tohoku University have identified a previously uncharacterized type of autophagy, during which an autophagic process termed chlorophagy removes collapsed chloroplasts in plant leaves. The findings could lead ...

Green algae and higher plants both harbor specialized cell organelles the chloroplasts in which photosynthesis takes place. This process allows these organisms to utilize energy from sunlight to power their biochemical ...

The discovery of a new gene is helping researchers at Michigan State University envision more-efficient molecular factories of the future.

University of Dundee scientists have solved a mystery concerning one of the most fundamental processes in cell biology, in a new discovery that they hope may help to tackle cancer one day.

Leading hospital "superbugs," known as the enterococci, arose from an ancestor that dates back 450 million yearsabout the time when animals were first crawling onto land (and well before the age of dinosaurs), according ...

A recent research paper in the Journal of Heredity reveals that there are three sub-species of snow leopard. Until now, researchers had assumed this species, Panthera uncia, was monotypic.

Adult stem cells have the ability to transform into many types of cells, but tracing the path individual stem cells follow as they mature and identifying the molecules that trigger these fateful decisions are difficult in ...

In their quest to replicate themselves, viruses have gotten awfully good at tricking human cells into pumping out viral proteins. That's why scientists have been working to use viruses as forces for good: to deliver useful ...

A UCLA study has found that a common strain of Caenorhabditis elegansa type of roundworm frequently used in laboratory research on neural developmenthas a pair of genes that encode both a poison and its antidote. The ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
Disentangling chloroplast genetics: Scientists isolate a critical gene ... - Phys.Org

BRIEF-CANCER GENETICS INC REPORTS Q1 LOSS PER SHARE $0.51 – Reuters

UPDATE 1-US Homeland Security: No announcement Friday on laptop ban expansion

WASHINGTON, May 12 U.S. Department of Homeland Security Secretary John Kelly is speaking with European officials on Friday to discuss threats to aviation and a possible expansion of a ban on in-cabin electronics larger than cellphones, U.S. and European officials said Friday.

View original post here:
BRIEF-CANCER GENETICS INC REPORTS Q1 LOSS PER SHARE $0.51 - Reuters

Cancer Genetics, Inc. Announces 15% Revenue Increase in First … – EconoTimes

Cancer Genetics, Inc. Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability

RUTHERFORD, N.J. and LOS ANGELES, May 11, 2017 -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today financial and operating results for the first quarterended March 31, 2017.

We are continuing to scale our revenue while making significant operational improvements as we execute on our vision to become the preeminent oncology diagnostics partner for biopharma companies, cancer centers and clinicians,said Panna Sharma, CEO and President of Cancer Genetics, Inc.We are growing market share in an industry undergoing a major transformation in its approach to oncology therapeutics development, clinical trials and patient monitoring. As the industry embraces precision medicine and individualized testing to drive higher standards of patient treatment and disease management, CGI is emerging as the diagnostic and testing partner of choice for biopharma companies, cancer centers and clinicians. Our team is actively working with 9 of the top 10 and 16 of the top 20 biopharma companies where we are providing critical molecular information and testing to help with clinical trials and in many cases developing innovative new tests and technologies to help improve patient diagnosis and monitoring.

The commitment we made to have the most comprehensive capabilities in oncology diagnostics continues with our launch into hereditary cancers with Focus::HERSite, further development into immuno-oncology through our Complete::IO panel, and the launch of our first liquid biopsy test, Liquid::Lung-cfDNA. Additionally, our partnerships to leverage artificial intelligence for clinical trial matching and drug development, is more evidence that we are building a leading and durable brand in precision oncology diagnostics. Our comprehensive, disease-focused oncology testing portfolio continues to grow, and covers 9 of the top 10 cancers, while we attract new clinical customers and deepen our relationships and projects with biopharma companies globally, continued Sharma.

FINANCIAL HIGHLIGHTS FOR THE QUARTER

Our efforts to drive revenue growth while improving operating efficiencies continues to accelerate, commented Sharma. Total operating expenses were reduced another 14% sequentially when compared to Q4 2016, and our loss from operations declined 46% from compared to Q1 2016, moving us closer to profitability. While net loss on a GAAP basis increased year-over-year to due to certain accounting treatment, its important to note that $7.5 million of the loss is related to non-cash charges from the change in fair value of derivative instruments. Quarter to quarter, these non-cash charges related to changes in our stock price may fluctuate significantly and impact GAAP net income and earnings per share.

FIRST QUARTER AND RECENT BUSINESS HIGHLIGHTS

The company reported total revenue of $7.0 million for the first quarter, compared to $6.1 million in Q1 2016, an increase of 15% year-over-year, driven by organic growth across all market categories: biopharma, clinical and discovery.

Revenue from biopharma partners and customers increased 11% to $3.7 million in the first quarter, compared to $3.4 million during Q1 2016. Additionally, the company increased the number of clinical studies and trials it is supporting to 140, up 12% from Q4 2016.

Clinical services revenue increased 20% in the first quarter of 2017 over the same period in 2016, from $2.5 million to $3.0 million. The growth was driven by an increase in clinical test volumes from 10,327 in Q1 2016 to 12,310 in the first quarter of 2017, an increase of 19%.

Discovery services contributed an additional $293 thousand in revenue for the first quarter of 2017, a 12% increase over Q1 2016, driven by significant demand for discovery solutions by research institutions where next-generation sequencing is combined with novel bioinformatics analysis. Discovery services, mostly performed in India, provides genomic and bioinformatics support for global discovery and pre-clinical initiatives.

Sharma continued, Our first quarter was marked by several important achievements and milestones. Were very pleased with the CLIA approval of our high performance next-generation immuno-oncology assay, Complete::IO, which meets the need for our customers to better monitor and stratify patient populations during immuno-oncology and immune therapy clinical trials, with the simultaneous detection of up to 10 markers on each cell. We also continue to gain traction on our solid tumor liquid biopsy testing platform with Liquid::Lung-cfDNA, which increases our ability to attract new customers and better service existing clients. The market for liquid biopsy solid tumor testing is expected to reach $20 billion by 2020. We are well positioned to capture market share. Given these market dynamics, we are confident that we are on the path to profitability.

Technologies and trends such as artificial intelligence, big-data, and combining genomic and immune-marker testing to improve patient outcomes and accelerate the discovery of new therapeutics are all areas that CGI is continuing to integrate into our business model and into our global business infrastructure. We believe our growing reach into the oncology ecosystem coupled with the strengthening of our operating fundamentals makes CGI a leader in developing and delivering oncology diagnostics from bench to bedside, concluded Sharma.

ABOUT CANCER GENETICS

Cancer Genetics, Inc. is an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:

Internet:www.cancergenetics.com Twitter:@Cancer_Genetics Facebook:www.facebook.com/CancerGenetics

Forward Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Non-GAAP Financial Information

In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures disclosed by the Company exclude the non- operating changes in the fair value of derivative instruments. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Management believes that these non-GAAP measures provide useful information about the Company's core operating results and thus are appropriate to enhance the overall understanding of the Company's past financial performance and its prospects for the future. The non-GAAP financial measures in this press release include Adjusted Net (Loss) and the related adjusted basic and diluted per share amounts.

Reconciliation from GAAP to Non-GAAP Results (in thousands, except per share amounts):

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

Read the original post:
Cancer Genetics, Inc. Announces 15% Revenue Increase in First ... - EconoTimes

Genetics determine how much coffee you can drink before it goes wrong – New York Post

The other day a patient came to see me concerned that every time he drank coffee, his heart seemed to twitch. Is this cardiac twitch a sign of heart disease? he asked. A doctor himself, he pointed to a study done in Zurich that suggested that drinking the equivalent of two cups of coffee reduced the bodys ability to boost blood flow to the heart muscle in response to exercise and that this caffeine effect was stronger at high altitudes. That got me a bit worried myself. Like many of us, I fancy myself an amateur barista. So how much should we be having?

When it comes down to it, the main active ingredient in coffee is caffeine. Caffeine is a plant alkaloid that occurs naturally in coffee, tea, guarana and kola nuts. Its considered the most widely used drug in the world. The good news is that caffeine improves lung function, helps glucose metabolism in the gut, aids athletic performance, and is used in medications for ailments like migraines. Many carbonated drinks also contain caffeine and when present, manufacturers automatically increase sugar content, as caffeine dulls sugar taste receptors. This increased sugar is what makes soda especially bad for you.

We metabolize caffeine at different speeds

It turns out that your cardiac twitch is related to your caffeine metabolism slow metabolizers of caffeine have a higher risk of heart attacks if they drink more than two cups of coffee per day; however, fast metabolizers have a reduced risk of a heart attack if they have at least a cup of coffee a day. I suggested that I run some genetic tests on my patient (and while I was at it, I thought Id test myself). Knowing your genetic type is important here, as when it comes to CYP1A2 and coffee, there are some interesting facts.

Those of us with the AA variant of the CYP1A2 gene are fast metabolizers, while those with the AC or CC subtypes of the gene are slow metabolizers. The risky ones are the GA or AA variants. My risk was not elevated, even if (in general) its best to limit caffeine to 300 to 400 milligrams each day. However, my patient had the GA variant, meaning that, if he drinks more than 200 milligrams of caffeine a day, his heart disease could end up being more than just a twitch.

The main varieties of coffee bean are Arabica or Robusta and the latter has twice the caffeine content. So how much caffeine does a cup of coffee have per cup? The results may surprise you:

Understanding your gene type and how much caffeine is in your favorite drink is important to make sure youre living your healthiest life especially if you love your coffee, as your genes may have other ideas for you.

Read more:
Genetics determine how much coffee you can drink before it goes wrong - New York Post

Bruker expands optical microscopy portfolio with Luxendo deal – Optics.org

12May2017

Acquisition of Heidelberg-based spin-out from the European Molecular Biology Laboratory should aid optogenetics, embryology, and other cutting-edge applications.

The US-headquartered microscope company Bruker has acquired Luxendo, a recent spin-out from the European Molecular Biology Laboratory (EMBL) that has developed a low-phototoxicity system based on light-sheet fluorescence.

Based in Heidelberg, Germany, Luxendo had raised 8million in venture finance as recently as January, saying that it needed the funds to expand sales, marketing and servicing activity related to its proprietary single plane illumination microscopy (SPIM) instruments after experiencing higher-than-expected demand from both academic and industrial customers.

The SPIM technology, which is equipped with two sCMOS cameras, is based around an inverted optical setup and comes with customizable laser illumination at up to eight different wavelengths.

The twin advantages of the approach, compared with regular laser scanning confocal microscopes, are that sampling time and phototoxicity and therefore damaging side effects to living specimens are both greatly reduced.

Luxendos microscopes are able to offer lower phototoxicity by only illuminating a sequential stack of thin slices of the organism being viewed at any one time.

This technology allows scientists to observe living organisms for extended periods of time without them being adversely impacted by phototoxicity, stated the firm previously.

Embryology to optogenetics For Bruker, the deal for an undisclosed sum represents the latest move to update its microscopy portfolio with innovative optical techniques aimed at applications such as live cell imaging and super-resolution microscopy.

In 2014 the Billerica, Massachusetts, firm acquired the University of Utah spin-out Vutara, whose research team had developed a 3D super-resolution technique based around a relatively powerful laser source.

And late last year Bruker commercialized an all-optical holographic module for stimulating and imaging multiple neurons in neural networks, targeting the fast-growing and high-profile market for optogenetics research.

Luxendos CEO Andreas Pfuhl says that light-sheet microscopy is revolutionizing the field of biological imaging, with the EMBL spin-out playing an influential role in its adoption for live-sample studies.

We feel that our history with EMBL has given us unique insights into what bio-imaging researchers need both right now and in the near future, he said. We are very gratified to join an internationally esteemed instrumentation company like Bruker, whose philosophy, culture and reputation so closely align with our research-oriented goals.

Much of the microscope development took place at EMBL, under the leadership of the labs cell biology and biophysics chief Lars Hufnagel, before Luxendo was founded in September 2015.

Portfolio transformation The SPIM microscopes are expected to improve Bruker's existing portfolio of swept-field confocal, super-resolution, and multiphoton fluorescence microscope product lines, enabling new research advances in small organism embryology, live-cell imaging, brain development and cleared brain tissue, and optogenetics applications.

This acquisition is another important step forward in Bruker's portfolio transformation, states the company, with Mark Munch, president of the Bruker NANO division, adding:

With its strong intellectual property position and unique SPIM technology, Luxendo has quickly established itself in the light-sheet microscopy market, particularly in Europe.

He adds that, like the Vutara acquisition, the new capabilities will provide synergies with the firms current microscopy products. We feel that we can take the business to the next level in both global market reach and next-generation development, which should greatly benefit our life sciences research customers, he said.

EMBLs director general Iain Mattaj added: It has been very rewarding to witness the rapid trajectory from pioneering technology developed at EMBL to Luxendo's well-designed, robust microscopes, and now this acquisition.

We anticipate that Bruker, with its excellent reputation in providing innovative technology, will make SPIM even more widely available. It will be truly exciting to see what the larger biological research community will discover with light-sheet microscopy.

More:
Bruker expands optical microscopy portfolio with Luxendo deal - Optics.org

Scientists unlock secret of chromosome copier – Phys.Org

May 12, 2017 by Grant Hill Credit: NIH

University of Dundee scientists have solved a mystery concerning one of the most fundamental processes in cell biology, in a new discovery that they hope may help to tackle cancer one day.

The process by which cells copy their own chromosomes and then make new cells is vital to all of life. Chromosomes contain the genetic blueprint that makes us what we are and this information must be copied perfectly for new cells to survive and carry out their function. When the copying process goes wrong, it can lead to cancer as abnormal cells are created.

Proteins in the cell combine to build a molecular 'machine' called the replisome, which plays a vital role in copying the double helix of DNA that is at the heart of each chromosome. The replisome is only built once during the life of each cell, and is then disassembled to ensure that cells just make one single copy of each chromosome.

Professor Karim Labib and colleagues in the School of Life Sciences at Dundee had previously studied this process in yeast, which is just one cell and is much easier to work with than human cells. They have now found that things are more complicated in animals, which have at least two different disassembly mechanisms. Importantly, the gene needed for one of these processes is lost in a number of human cancers, suggesting a new approach by which these particular tumours could be treated.

"Ever since Watson and Crick first described the structure of DNA we have known that cells copy chromosomes, but we are still learning how it works," said Professor Labib.

"By looking at yeast, which is very similar genetically to humans, we discovered that one of the many components of the replisome undergoes a change called 'ubiquitylation', after the chromosomes have been copied, which marks the replisome for disassembly by the cell's recycling machinery. This is a good thing, as genetic studies show that if the replisome is not taken apart but instead remains glued to the chromosomes, then this can lead to major problems.

"What we have now discovered is that the machinery that marks the yeast replisome for destruction doesn't exist in animals, so there had to be something else driving this process. By studying a small worm called Caenorhabditis elegans we found that animals actually have two different mechanisms for replisome dissassembly. If one pathway fails to do its job then the second kicks in as a back-up.

"What makes this particularly interesting is that a gene required for the second mechanism is known to be mutated in a variety of human cancers, including some lymphomas, glioblastomas and myelomas. Our work with this gene in worms suggests a new way to treat the corresponding cancers in humans.

"If we partially inactivate the genes involved in either the first or the second pathway for replisome disassembly then worms are fine, but inhibiting both at the same time is lethal. Translating this idea to humans, a drug that inhibits the first pathway should specifically kill tumour cells that lack the second pathway, without hurting the rest of the body."

The work is another significant step towards understanding the processes at the heart of human cells, which is vital for developing new treatments to tackle diseases. In almost all instances of cancer development, errors in the chromosome copying machinery can be seen in the early stages.

"One of the goals in cancer research is to understand the normal biology that goes wrong in cancer cells, because only then can we look for better ways to kill cancer cells without hurting the rest of our body," continued Professor Labib. "This area of chromosome replication has been of major interest for the last couple of decades, as we uncover more and more about how it works.

"Copying chromosome badly leads to mutations and mutations lead to cancer. Cells divide when shouldn't and lose identity, leading to them breaking off and floating round our bodies in blood and the lymphatic system metastasis occurs.

"The challenge in treating cancer is to find a way to kill part of you without killing all of you. The goal is to find cleverer forms of chemotherapy that kills cancer cells but not healthy ones. The problem is that have the same DNA, as you so what we need to do is find out what makes them different and target any Achilles heel we think we can find."

The paper is published in the latest edition of the journal Nature Cell Biology.

Explore further: Scientists have discovered a code of signals that regulates genome duplication

More information: Remi Sonneville et al. CUL-2LRR-1 and UBXN-3 drive replisome disassembly during DNA replication termination and mitosis, Nature Cell Biology (2017). DOI: 10.1038/ncb3500

Three years ago, the research team directed by scar Fernndez-Capetillo, head of the Genomic Instability Group at the Spanish National Cancer Research Centre (CNIO), obtained, for the first time, a panoramic view of the ...

Aneuploidy is a condition in which cells contain an abnormal number of chromosomes, and is known to be the cause of many types of cancer and genetic disorders, including Down Syndrome. The condition is also the leading cause ...

Scientists have uncovered how tumours are able to grow despite significant damage to the structure and number of their chromosomes - the storage units of DNA - according to two new studies published in Cancer Cell and Cancer ...

Scientists at the University of Dundee have discovered that "molecular scissors" that repair damaged and abnormal DNA are critical for keeping cancers at bay.

A recent research study at The Hormel Institute, University of Minnesota is providing insight into the regulation of chromosome segregation and the mechanisms used by cells to prevent them from forming tumors.

Bowel cancer cells missing one of three genes can rapidly reshuffle their genetic 'pack of cards' the chromosomes that hold the cell's genetic information. This reshuffling has been previously shown to render tumours ...

University of Dundee scientists have solved a mystery concerning one of the most fundamental processes in cell biology, in a new discovery that they hope may help to tackle cancer one day.

Leading hospital "superbugs," known as the enterococci, arose from an ancestor that dates back 450 million yearsabout the time when animals were first crawling onto land (and well before the age of dinosaurs), according ...

A recent research paper in the Journal of Heredity reveals that there are three sub-species of snow leopard. Until now, researchers had assumed this species, Panthera uncia, was monotypic.

Adult stem cells have the ability to transform into many types of cells, but tracing the path individual stem cells follow as they mature and identifying the molecules that trigger these fateful decisions are difficult in ...

In their quest to replicate themselves, viruses have gotten awfully good at tricking human cells into pumping out viral proteins. That's why scientists have been working to use viruses as forces for good: to deliver useful ...

A UCLA study has found that a common strain of Caenorhabditis elegansa type of roundworm frequently used in laboratory research on neural developmenthas a pair of genes that encode both a poison and its antidote. The ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Continue reading here:
Scientists unlock secret of chromosome copier - Phys.Org

Global Cell Culture Protein Surface Coating Market – Analysis, Technologies & Forecasts to 2021 – Increasing … – PR Newswire (press release)

The global cell culture protein surface coating market to grow at a CAGR of 13.20% during the period 2017-2021.

The report, Global Cell Culture Protein Surface Coating Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in market is increasing preference for 3D cell culture over 2D cell cultures. The improvement in different cell culture techniques has created a great opportunity for drug discovery and life sciences. 3D cell cultures are increasingly adopted as they have the potential to overcome the challenges of 2D cell culture. Biological cells in a 3D cell culture are grown under controlled conditions, where cells can interact with their surroundings in all three dimensions. This type of culture is widely used in tissue engineering, drug development, regenerative medicine, and clinical trials.

Many vendors are intensively focusing on research to introduce innovative 3D cell culture systems and related products. Here, 3D cell culture protein surface coatings play a vital role in the R&D of drugs as they provide a natural environment for culturing cells. Also, these are extensively used for cell biology studies, molecular biology research, and genetic engineering applications as they provide better adhesion for cells and facilitate precise analysis. For instance, 3D cell culture is widely used in determining drug testing results before human or animal clinical trials, when compounds that are most likely used to work or fail early in the drug testing process. These better results will help save millions of dollars in the drug development process, which will reduce the number of animals utilized in drug testing process.

Key Market Trends:

Key vendors

Other prominent vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview: Cell culture surfaces

PART 06: Market landscape

PART 07: Market segmentation by product type

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/5677c6/global_cell

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cell-culture-protein-surface-coating-market---analysis-technologies--forecasts-to-2021---increasing-preference-for-3d-cell-culture-over-2d-cell-cultures---research-and-markets-300455839.html

SOURCE Research and Markets

http://www.researchandmarkets.com

See the original post here:
Global Cell Culture Protein Surface Coating Market - Analysis, Technologies & Forecasts to 2021 - Increasing ... - PR Newswire (press release)